MedTrace Logo

Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

NCT07444073 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2026-03-02

No results posted yet for this study

Summary

This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.

Conditions

  • Aging
  • Obesity & Overweight

Interventions

OTHER

Not applicable. This is an observational study.

Not applicable. This is an observational study.

Sponsors & Collaborators

Principal Investigators

  • Jan Gruber, PhD · National University of Singapore

Eligibility

Min Age
40 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07444073 on ClinicalTrials.gov